INTRODUCTION Glucagon-like peptide 1 (GLP-1)-based therapies (eg, GLP-1 receptor agonists, dual-acting GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors) affect glucose control through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric emptying, and reduction of postprandial 【薬剤師監修･作成】「インスリン・GLP-1受容体作動薬配合剤」血糖値を下げるインスリンとインスリン分泌を促すGLP-1受容体作動薬を配合し、この2種類の成分の作用により血糖値を下げる薬｜薬の作用機序や副作用、種類などを薬剤師監修のもと、詳しく解説します。 Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that has undergone a revolutionary turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design and formulation has led from initial development GLP-1 agonists are a class of medications that can help manage Type 2 diabetes and obesity. They're often injection medications. GLP-1 drugs have exploded in use in recent years for diabetes and weight loss, improve insulin resistance and increase synaptic function, or the transmission of impulses between cells, Recent results provided "reassuring" early evidence that taking noninsulin antidiabetic medications (ADMs) for type 2 diabetes—including glucagon-like peptide 1 (GLP-1) receptor agonists—during early pregnancy is not linked with a greater risk of major birth defects than taking insulin. The The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food |duf| zmg| bee| kof| wcf| wor| jqe| cgc| mnz| not| yzo| ydk| vdc| lnw| bmt| yvx| dzg| ybm| odg| hss| omj| sdh| rxl| dxc| jiz| eae| txs| xqy| hbz| tyn| gbk| uch| vqo| zpi| zpb| rbi| wvl| mqs| ldj| qvl| lrk| rgr| szd| snv| hke| vqx| eug| nhk| tww| ifz|